Pathogenetic treatment of patients with COVID-19 at the outpatient stage


ABSTRACT. It has been over 2 years since the world run into coronavirus disease (COVID-19), but the pandemic is still going. Today we have a much better understanding of the pathogenesis of the disease and immune defense mechanisms, which opens up new possibilities for the pathogenetic treatment of coronavirus infection. It is known that COVID-19 often has a wavy course: the first wave, which is characterized by mild symptoms, after a temporary improvement passes into the second wave (so-called pulmonary phase), which is much more severe and often fatal. Therefore, it is important to prescribe effective treatment at the early stage of COVID-19, which will allow to change the trajectory of the first wave and prevent its transition to the fatal “ninth shaft”. This can be achieved by inhibiting the replication of SARS-CoV-2 virus with etiotropic therapy, and by using of complex pathogenetic therapy to suppress inflammation and prevent cytokine storm, to protect pneumocytes, to minimize the effects of oxidative stress, possible interruption of the coagulation system. This complex approach is especially important for elderly patients or those with chronic cardiovascular, bronchopulmonary and endocrine diseases. In this review, we present the evidence base for the effectiveness of COVID-19 pathogenetic therapy. We hope that the presented therapeutic strategy will help physicians to improve the effectiveness of outpatient management of patients with coronavirus infection.

Keywords: COVID-19, SARS-CoV-2, pathogenesis, pathogenetic therapy, cytokine storm, oxidative stress, immunotrombosis


Liu Y., et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur. Respir. J. 2020; 55 (5): 2000547. doi: 10.1183/13993003.00547-2020.

Xu Z., et al. Using artificial intelligence to detect COVID-19 and community-acquired pneumonia based on pulmonary CT: evaluation of the diagnostic accuracy. Radiology. 2020; 296 (2): E65-E71. doi: 10.1148/radiol.2020200905.

Cugno M., Gualtierottiab R., Griffinib S., et al. Complement activation and endothelial perturbation parallel COVID-19 severity and activity. Journal of Autoimmunity. 2021; 116: 102560. doi: 10.1016/j.jaut.2020.102560.

Tang N., Bai H., Xing Chen, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. Journal of Thrombosis. 2020; 18 (5): 1094-1099. doi: 10.1111/jth.14817.

Marietta M., Ageno W., Artoni A., et al. COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). Blood Transfus. 2020; 18 (3): 167-169. doi: 10.2450/2020.0083-20.

Di Minno A., Ambrosino P., Calcaterra I., Di Minno M.N.D. COVID-19 and venous thromboembolism: a meta-analysis of literature studies. Semin. Thromb. Hemost. 2020; 46 (7): 763-771. doi: 10.1055/s-0040-1715456.

Nicolai L., Leunig A., Brambs S., Kaiser R. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020; 142 (12): 1176-1189. doi: 10.1161/CIRCULATIONAHA.120.048488.

Skendros P., Mitsios A., Chrysanthopoulou A., Mastelos D., Rittis K. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 2020; 30 (11): 6151-6157. doi: 10.1172/JCI141374.

Zhang L., Feng X., Zhang D., et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: prevalence, risk factors, and outcome. Circulation. 2020 Jul 14; 142 (2): 114-128. doi: 10.1161/CIRCULATIONAHA.120.046702.

Mehta P., Randy M., Cron Q., et al. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. The Lancet Rheumatology. 2020; 2 (6): e358-e367. doi: 10.1016/S2665-9913(20)30096-5.

Varga Z., Flammer A.J., Steiger P., Haberecker M., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395 (10234): 1417-1418. doi: 10.1016/S0140-6736(20)30937-5.

Iba T., Levy J.H., Connors J.M., Warkentin T.E., Thachil J., Levi M. The unique characteristics of COVID-19 coagulopathy. Crit. Care. 2020; 24 (1): 360. doi: 10.1186/s13054-020-03077-0.

Zhou F., Yu T., Du R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.

Ortiz-Diaz E.O., Cai-Ng S., Pirtle P., Sprouse M. Successful treatment of acute chest syndrome and preeclampsia with delivery, proning, and exchange transfusion. American Thoracic Society International Conference Abstracts. 2020. doi: 10.1164/ajrccm-conference.2020.201.1.

Lipworth B., Chan R., Lipworth S., RuiWen Kuo C. Weathering the cytokine storm in susceptible patients with severe SARS-CoV-2 infection. J. Allergy Clin. Immunol. Pract. 2020; 8 (6): 1798-1801. doi: 10.1016/j.jaip.2020.04.014.

Lynnyk M.I., Yashyna L.O., Ignatieva V.I. ta in. Osoblyvosti perebihu nehospitalnoi pnevmonii virusnoi etiolohii COVID-19 u patsiientiv z bronkhialnoiu astmoiu. Astma ta alerhiia. 2022; 1-2: 15-26. doi: 10.31655/2307-3373-2022-1-2-15-26.

Peters M., et al. COVID-19-related genes in sputum cells in asthma. Relationship to demographic features and corticosteroids. American Journal of Respiratory and Critical Care Medicine. 2020; 202 (1). doi: 10.1164/rccm.202003-0821OC.

Matsuyama S., Kawase M., Nao N., et al. The inhaled corticosteroid ciclesonide blocks coronavirus RNA replication by targeting viral NSP15. J. Virol. 2020; 95 (1): e01648-20. doi: 10.1128/JVI.01648-20.

Pertseva T.O., Konopkina L.I., Bielosludtseva K.O., Shchudro O.O., Fuhol K.V. Ventyliatsiini ta dyfuziini porushennia v osib, shcho perenesly nehospitalnu pnevmoniiu, asotsiiovanu z koronavirusnoiu khvoroboiu (COVID-19): mozhlyvosti inhaliatsiinoi terapii. Astma ta alerhiia. 2021; 4: 27-42. doi: 10.31655/2307-3373-2021-4-27-42.

RECOVERY Collaborative Group, Horby P., Lim W.S., et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021; 384 (8): 693-704. doi: 10.1056/NEJMoa2021436.

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Sterne J.A.C., Murthy S., et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020; 324 (13): 1330-1341. doi: 10.1001/jama.2020.17023.

Ramakrishnan S., Nicolau D.V.Jr., Langford B., et al. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomized controlled trial. Lancet Respir. Med. 2021; 9 (7): 763-772. doi: 10.1016/S2213-2600(21)00160-0.

Zaikov S.V. Inhaliatsiini kortykosteroidy v likuvanni patsiientiv z COVID-19. Astma ta alerhiia. 2021; 3: 5-15. doi: 10.31655/2307-3373-2021-3-5-15.

Poe F.L., Corn J. N-acetylcysteine: a potential therapeutic agent for SARS-CoV-2. Med. Hypotheses. 2020; 143: 109862. doi: 10.1016/j.mehy.2020.109862.

Mereto G.C., Balestra L., Henriquet F. Alveolar surfactant in lungs of operated patients after acetylcysteine treatment. Eur. J. Respir. Dis. Suppl. 1980; 111: 160-1.

Zhang Q., Ju Y., Ma Y., Wang T. N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: a randomized controlled trial. Medicine (Baltimore). 2018; 97: e13087. doi: 10.1097/MD.0000000000013087.

Mokhtari V., Afsharian P., Shahhoseini M., Kalantar S.M., Moini A. A review on various uses of N-acetyl cysteine. Cell J. 2017 Apr-Jun; 19 (1): 11-17. doi: 10.22074/cellj.2016.4872.

Gaynitdinova V.V., Avdeev S.N., Merzhoeva Z.M., Berikkhanov Z.G., Medvedeva I.V., Gorbacheva T.L. N-acetylcysteine as a part of complex treatment of moderate COVID-associated pneumonia. Pulmonologiya. 2021; 31 (1): 21-29.

Dutov A.A., Nikitin D.A., Lukyanova Yu.L. N-atsetiltsistein: farmakokineticheskie parametry i vliyanie na kontsentratsiyu endogennykh aminotiolov. Farmakokinetika i farmokodinamika. 2016; 2: 26.

Kabinet Ministriv Ukrainy (2020b). Postanova Kabinetu Ministriv Ukrainy vid 28.10.2020 № 1033 “Pro vnesennia zmin do perelikiv, zatverdzhenykh postanovamy Kabinetu Ministriv Ukrainy vid 20 bereznia 2020 r. № 224 ta 225”.

Lana J.F.S.D., Lana A.V.S.D., Rodrigues Q.S., et al. Nebulization of glutathione and N-acetylcysteine as an adjuvant therapy for COVID-19 onset. Adv. Redox. Res. 2021; 3: 100015. doi: 10.1016/j.arres.2021.100015.

Bezditko T.V., Novikova I.V., Yeromenko H.V. ta in. Reabilitatsiia khvorykh na COVID-19 z vykorystanniam kompleksu aminokyslot, vitaminiv ta mikroelementiv. Astma ta alerhiia. 2022; 1-2: 27-34. doi: 10.31655/2307-3373-2022-1-2-27-34.

Fiorentino G., Coppola A., Izzo R., et al. Effects of adding L-arginine orally to standard therapy in patients with COVID-19: a randomized, double-blind, placebo-controlled, parallel-group trial. Results of the first interim analysis. EClinicalMedicine. 2021 Oct; 40: 101125. doi: 10.1016/j.eclinm.2021.101125.

How to Cite
Ostrovskyi, M., Konopkina, L., Gashynova, K., Gumeniuk, G., Dobrianskyi, D., & Bororova, O. (2022). Pathogenetic treatment of patients with COVID-19 at the outpatient stage. Infusion & Chemotherapy, (1), 23-31.

Author Biographies

M.M. Ostrovskyi, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine

Ostrovskyi Mykola Mykolaiovych
Head of the Department of tuberculosis and pulmonology with a course
of occupational diseases
MD, professor.
17, I. Franko st., Ivano-Frankivsk, 76018, Ukraine.

L.I. Konopkina, Dnipro State Medical University, Dnipro, Ukraine

Konopkina Liudmyla Ivanivna
Head of the Department of internal medicine 1,
MD, professor.
9, Vernadskogo st., Dnipro, 49044, Ukraine.

K.Yu. Gashynova, Dnipro State Medical University, Dnipro, Ukraine

Gashynova Kateryna Yuriivna
Head of the Department of Occupational Diseases, Clinical Immunology and Clinical Pharmacology
MD, professor.
9, Vernadskogo st., Dnipro, 49044, Ukraine.

G.L. Gumeniuk, National University of Healthcare of Ukraine named after P.L. Shupyk, Kyiv, Ukraine

Gumeniuk Galyna Lvivna
Professor of the Department of tuberculosis and pulmonology; Senior Researcher of the Department of diagnosis, treatment and clinical pharmacology of lung disease NIFP NAMNU.
MD, professor.
10, M. Amosova st., Kyiv, 03038, Ukraine.

D.V. Dobrianskyi, National Medical University named after O.O. Bohomolets, Kyiv, Ukraine

Dobrianskyi Dmytro Viktorovych
Associate professor, Department of internal medicine № 3
PhD, docent.
13, T. Shevchenko blvd., Kyiv, 01601, Ukraine.

O.L. Bororova, SI “National Institute of Phthisiology and Pulmonology named after F.G. Yanovsky of the NAMS of Ukraine”, Kyiv, Ukraine

Bororova Olena Leonidivna
Junior researcher, Department of treatment technologies for nonspecific lung diseases
10, M. Amosova st., Kyiv, 03038, Ukraine

Most read articles by the same author(s)